
Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>




































This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 70.4 kDa. The protein migrates as 86-116 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>98% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:

Human TrkB, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 98%.

Immobilized Human BDNF, premium grade (Cat. No. BDF-H5219) at 2 μg/mL (100 μL/well) can bind Human TrkB, Fc Tag (Cat. No. NT2-H5254) with a linear range of 1-20 ng/mL (Routinely tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
| English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Entrectinib | NMS-E628; RXDX-101; RG-6268 | Approved | Nerviano Medical Sciences Srl | Rozlytrek, 罗圣全 | Mainland China | Solid tumours | Roche (China) Holding Ltd | 2019-06-18 | Breast Neoplasms; Thyroid Cancer, Papillary; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Large-Cell, Anaplastic; Leukemia, Myeloid, Acute; Hepatic Insufficiency; Colorectal Neoplasms; Brain Neoplasms; Sarcoma; Cholangiocarcinoma; Solid tumours; Central Nervous System Neoplasms; Neuroendocrine Tumors; Salivary Gland Neoplasms; Pancreatic Neoplasms; Neoplasms; Carcinoma, Renal Cell; Head and Neck Neoplasms; Ovarian Neoplasms; Skin Melanoma | Details |
| Cabozantinib S-malate | XL-184; BMS-907351 | Approved | Exelixis Inc | Cometriq, Cabometyx | Japan | Carcinoma, Renal Cell | Takeda | 2012-11-29 | Osteosarcoma; Thyroid Neoplasms; Gliosarcoma; Colorectal Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Hepatic Insufficiency; Astrocytoma; Breast Neoplasms; Sarcoma, Ewing; Lymphoma; Carcinoma, Adenosquamous; Adenocarcinoma, Clear Cell; Sarcoma, Clear Cell; Medullary thyroid cancer (MTC); Cholangiocarcinoma; Prostatic Neoplasms; Neurofibroma, Plexiform; Urethral Neoplasms; Carcinoma, Neuroendocrine; Meningioma; Carcinoma, Non-Small-Cell Lung; Paraganglioma; Melanoma; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Adenocarcinoma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Neuroblastoma; Glioma; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lung Neoplasms; Sarcoma, Alveolar Soft Part; Uterine Neoplasms; Fallopian Tube Neoplasms; Carcinoid Tumor; Neurofibromatoses; Seminoma; Carcinoma, Transitional Cell; Glioblastoma; Rejection of liver transplantation; Carcinoma, Merkel Cell; Hepatoblastoma; Pain; Pheochromocytoma; Neoplasms; Carcinoma, Renal Cell; B | Details |
| Larotrectinib sulfate | LOXO-101; ARRY-470; BAY-2757556 | Approved | Array Biopharma | Vitrakvi, 维泰凯 | Mainland China | Solid tumours | Bayer Healthcare Company Ltd | 2018-11-26 | Endometrial Neoplasms; Sarcoma, Ewing; Neuroblastoma; Sarcoma; Histiocytosis, Langerhans-Cell; Breast Neoplasms; Cholangiocarcinoma; Prostatic Neoplasms; Histiocytic Sarcoma; Colorectal Neoplasms; Neoplasms, Neuroepithelial; Lung Neoplasms; Uterine Neoplasms; Osteosarcoma; Lymphoma; Lymphoma, Non-Hodgkin; Glioma; Carcinoma, Squamous Cell; Thyroid Neoplasms; Esophageal adenocarcinoma; Melanoma; Neoplasms, Germ Cell and Embryonal; Xanthogranuloma, Juvenile; Uterine Cervical Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Rectal Neoplasms; Fibrosarcoma; Rhabdomyosarcoma; Liver Neoplasms; Leukemia; Ovarian Neoplasms; Medulloblastoma; Solid tumours; Hepatoblastoma; Rhabdoid Tumor; Carcinoma, Renal Cell; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ependymoma; Stomach Neoplasms; Skin Neoplasms; Wilms Tumor; Carcinoma, Transitional Cell; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Multiple | Details |
| English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| ACD-856 | ACD-856 | Alzecure Pharma Ab | Details | ||
| Lestaurtinib | SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd | Leukemia; Leukemia, Myeloid; Bone Marrow Neoplasms; Polycythemia Vera; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Psoriasis; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential | Details |
| HG-030 | HG-030 | Phase 1 Clinical | Hitgen Inc | Solid tumours | Details |
This web search service is supported by Google Inc.




